• If you are wondering whether Quest Diagnostics at around US$190.84 per share offers good value today, it helps to step back and look at the stock through a few different valuation lenses.
• The share price has seen mixed recent returns, with a 1.7% decline over 7 days and a 3.0% decline over 30 days, set against a 9.8% gain year to date and 10.4% over the past year, plus longer term returns of 54.8% over 3 years and 53.1% over 5 years.
• Recent coverage has focused on Quest Diagnostics as a US healthcare stock that investors follow for its role in diagnostics and testing services. This can shape how the market thinks about its resilience and long term demand. Broader sector discussions and periodic updates on healthcare spending trends have also framed how investors weigh its long term prospects against current pricing.
• Today, Quest Diagnostics holds a value score of 5/6. This raises an important question about what traditional metrics like P/E and discounted cash flow really say about the stock and whether there is an even better way to think about value that will be returned to at the end of this article.

Approach 1: Quest Diagnostics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and then discounting them back to today’s value.

For Quest Diagnostics, the model used is a 2 Stage Free Cash Flow to Equity approach. The company’s latest twelve month free cash flow stands at about $1.36b. Analyst inputs and Simply Wall St extrapolations project free cash flow through to 2035, with estimated figures such as $1.45b in 2026 and $1.70b in 2035, all expressed in today’s money using discounting.

When all those discounted cash flows are added together, the model arrives at an estimated intrinsic value of about $318.98 per share. Compared with the current share price of around $190.84, this implies an intrinsic discount of roughly 40.2%, which indicates that the stock is trading below the DCF estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Quest Diagnostics is undervalued by 40.2%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Quest Diagnostics Price vs Earnings

For a profitable company like Quest Diagnostics, the P/E ratio is a straightforward way to gauge how much you are paying for each dollar of earnings. Investors usually accept a higher P/E when they expect stronger growth or lower risk, and a lower P/E when growth expectations are more modest or perceived risk is higher.

Quest Diagnostics currently trades on a P/E of about 20.71x. That sits below the Healthcare industry average of around 22.13x and below the peer group average of roughly 31.11x. This suggests the stock is priced more conservatively than many of its peers on earnings.

Simply Wall St’s Fair Ratio for Quest Diagnostics is 23.57x. This is a proprietary P/E estimate that reflects factors such as the company’s earnings growth profile, profit margins, industry, market capitalization and risk characteristics. Because it is tailored to the company’s fundamentals, the Fair Ratio can give a more targeted reference point than simply comparing the stock to broad industry or peer averages. Since the current P/E of 20.71x sits below the Fair Ratio of 23.57x, the stock appears to trade at a discount to this earnings based reference point.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Quest Diagnostics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are a clear story you attach to Quest Diagnostics that links your view of its future revenue, earnings and margins to a financial forecast and a fair value. This is all done within a simple tool on Simply Wall St’s Community page that millions of investors use to compare their own fair value with the current share price and see whether they think the stock is cheap or expensive. Each Narrative is automatically refreshed when new information such as earnings or guidance arrives. Some investors might build a bullish Quest Diagnostics Narrative around higher test volumes, data analytics and acquisitions that support a fair value near the upper analyst target of about US$235 per share. More cautious investors might focus on reimbursement pressure, payer mix shifts and higher costs and lean toward a fair value closer to the lower analyst target of roughly US$184.

Do you think there's more to the story for Quest Diagnostics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.